Liz is a Senior Scientist at Pfizer, holds a B.S. in Diagnostic Genetic Sciences from the University of Connecticut and has been working in Genetic Toxicology at Pfizer for over 25 years. Current responsibilities include serving as study director of the iScreen, a multi-endpoint imaging assay, as a POA for the ex vivo portion of the Big Blue Assay, and as genetic toxicology liaison to the anti-infective and hospital therapeutic areas. Liz also works on developmental projects involving data management, 6-well Ames imaging, continuous improvement of routine assays and serves as an image analysis specialist to groups within Drug Safety and Development. Currently Liz serves on the EMGS (Environmental and Mutagenesis Society) 2024 program committee and is a board member of the Genetic Toxicology Association. Liz has been an SBI2 member since its founding and served on the SBI2 board as Secretary and program committee member from 2015 to 2017. Areas of interest presently are utilizing HepaRG cells in 2D and 3D formats for genetic tox endpoints, as well as diving deeper into data management and visualizations with Tibco Spotfire. SBI2 has been Liz’s favorite scientific association since it’s inception due to the focus on technological development, education and quantitative high content analysis.